MedTrace Logo

Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study

NCT00255463 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 185

Last updated 2009-04-23

No results posted yet for this study

Summary

The purpose of this study is to compare the changes in a proliferation biomarker in subjects receiving Anastrozole or Anastrozole/ZD1839 combination.

Conditions

Interventions

DRUG

Anastrazole

DRUG

Gefitinib

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca Iressa Medical Sciences Director, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Completion
2005-11-30

Countries

  • Czechia
  • France
  • Hungary
  • Portugal
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00255463 on ClinicalTrials.gov